Estrella Immunopharma, Inc.

ESLA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.7353

−$0.0097 · -1.30%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

26/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Expensive

Momentum

Weakening

Sentiment

Mixed

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Cheng Liu
Listed since: Sep 14, 2021
Employees: 3

Market position

Day range

Current $0.7353

$0.7205$0.7605

52-week range

Current $0.7353

$0.678$3.15

Open: $0.7605
Previous close: $0.745
Volume: 8.19K; 0.21× average
Average volume: 39.12K; Average daily volume
Market cap: 31.37M USD
Beta: 0.89; Market reference 1
50-day average: $0.8475; -13.24% below average
200-day average: $1.284; -42.73% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 56.06M USD
P/E (TTM): -2.99×
P/B (TTM): -4.25×
P/S (TTM): 0×
EV / EBITDA: -4.29×
Earnings yield: -22.74%
Free cash flow yield: -3.11%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: 126.02%
Return on assets: -411.19%
Return on invested capital: 126.01%

Financial health

Debt / equity: 0×
Current ratio: 0.12×
Altman Z-score: -52.47
Piotroski F-score: 2 of 9

Financial statements

Income trends

Operating income

−13.06M USD-47.67%

Net income

−13.06M USD-47.65%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	10.25M USD	6.41M USD	4.11M USD	10.45M USD	1.39M USD
Selling, general, and administrative	2.81M USD	2.44M USD	3.2M USD	663.19K USD	296.25K USD
Operating expenses	13.06M USD	8.85M USD	7.31M USD	1.57M USD	1.69M USD
Interest income	—	—	—	654.07K USD	1.43K USD
Depreciation and amortization	—	—	—	228.49K USD	236.56K USD
Operating income	−13.06M USD	−8.85M USD	−7.31M USD	−1.57M USD	−1.69M USD
Net income	−13.06M USD	−8.85M USD	−7.31M USD	−996.1K USD	−1.69M USD